{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "marketState": "CLOSED", "regularMarketChangePercent": 15.435357, "regularMarketPrice": 17.5, "exchange": "LSE", "shortName": "KALA PHARMACEUTICALS INC KALA P", "longName": "Kala Pharmaceuticals, Inc.", "messageBoardId": "finmb_83652421", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketTime": 1683899894, "earningsTimestamp": 1683633600, "earningsTimestampStart": 1691584200, "earningsTimestampEnd": 1692016200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "bookValue": 11.116, "fiftyDayAverage": 15.122374, "fiftyDayAverageChange": 2.3776264, "fiftyDayAverageChangePercent": 0.15722574, "twoHundredDayAverage": 16.68969, "twoHundredDayAverageChange": 0.81031036, "twoHundredDayAverageChangePercent": 0.048551552, "priceToBook": 1.5743073, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1517212800000, "priceHint": 2, "regularMarketChange": 2.3400002, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 280, "regularMarketPreviousClose": 15.16, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 1130, "averageDailyVolume10Day": 635, "fiftyTwoWeekLowChange": 17.5, "fiftyTwoWeekRange": "0.0 - 41.5", "fiftyTwoWeekHighChange": -24.0, "fiftyTwoWeekHighChangePercent": -0.57831323, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 41.5, "symbol": "0JQ2.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1167 Massachusetts Avenue", "city": "Arlington", "state": "MA", "zip": "02476", "country": "United States", "phone": "781 996 5252", "fax": "781 642 0399", "website": "https://www.kalarx.com", "industry": "", "sector": "", "longBusinessSummary": "Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 34, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark T. Iwicki", "age": 56, "title": "Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 1097496, "fmt": "1.1M", "longFmt": "1,097,496"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Todd  Bazemore", "age": 52, "title": "Pres & COO", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 783040, "fmt": "783.04k", "longFmt": "783,040"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kim  Brazzell Ph.D.", "age": 69, "title": "Head of R&D and Chief Medical Officer", "yearBorn": 1953, "fiscalYear": 2022, "totalPay": {"raw": 750912, "fmt": "750.91k", "longFmt": "750,912"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Justin  Hanes Ph.D.", "title": "Founder & Chair of the Scientific Advisory Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Mary  Reumuth CPA, CPA", "age": 47, "title": "CFO & Treasurer", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jill S. Steier", "title": "Exec. Director of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eric L. Trachtenberg", "age": 49, "title": "Gen. Counsel, Chief Compliance Officer & Corp. Sec.", "yearBorn": 1973, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Vincent  Kosewski", "age": 59, "title": "Sr. VP of Manufacturing & Supply Chain Management", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James  Patnoe", "title": "Sr. VP of Market Access, Commercial Operations & Pricing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Darius  Kharabi J.D., M.B.A.", "age": 43, "title": "Chief Bus. Officer", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}